Gilead Sciences (GILD)
NASDAQ: GILD · Biotechnology · Foster City, CA
Our rating: Neutral
Call changed from Positive to Neutral at $170.33, moderate conviction, November 2, 2026.
Breaks if: The Neutral call turns Positive if reported revenue growth reaches 5% or above for two consecutive quarterly prints, or if an oncology pipeline asset delivers a Phase 3 primary endpoint and label expansion within the next 12 months. It flips Cautious if free cash flow margin falls below 25% for two straight quarters, or if the HIV segment posts a year-over-year revenue decline of 5% or more in any single quarter — either condition would undercut the durability thesis that supports the current multiple.
Key figures
| Market value | $206.4B |
|---|---|
| Revenue, last 12 months | $31.0B |
| Net income, last 12 months | −$3.9B |
| Free cash flow, last 12 months | $13.8B |
| Price to earnings | n/a |
| Free cash flow yield | 6.7% |
| Dividend yield | 2.0% |
| Operating margin | −7.6% |
| Return on equity | −22.3% |
| Beta to the S&P 500 | 0.33 |
| Volatility, annualized | 27.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $8.3B | 6.8% | $1.94 | $4.8B |
| June 30, 2026 | $7.8B | 10.2% | $-8.45 | $3.4B |
| March 31, 2026 | $7.0B | 4.4% | $1.61 | $2.4B |
| December 31, 2025 | $7.9B | 4.7% | $1.74 | $3.1B |
| September 30, 2025 | $7.8B | 3.0% | $2.43 | $4.0B |
| June 30, 2025 | $7.1B | 1.8% | $1.56 | $720M |
| March 31, 2025 | $6.7B | −0.3% | $1.04 | $1.7B |
| December 31, 2024 | $7.6B | 6.4% | $1.42 | $2.8B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $8.44B: Claude 55%, Gemini 80%, Mistral 78%
- Diluted earnings per share are at least $1.74: Claude 52%, Gemini 70%, Mistral 70%
- Free cash flow for the quarter is at least $3.12B: Claude 55%, Gemini 88%, Mistral 72%
18 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.